首页> 外文OA文献 >The synergy of panobinostat plus doxorubicin in acute myeloid leukemia suggests a role for HDAC inhibitors in the control of DNA repairSynergy of panobinostat and doxorubicin in AML

【2h】

The synergy of panobinostat plus doxorubicin in acute myeloid leukemia suggests a role for HDAC inhibitors in the control of DNA repairSynergy of panobinostat and doxorubicin in AML

机译：Panobinostat和阿霉素在急性髓细胞白血病中的协同作用表明HDAC抑制剂在控制DNA修复中发挥作用Panobinostat和阿霉素在AML中协同作用

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Maiso, Patricia; Colado, Enrique; Ocio, Enrique M.; Garayoa, Mercedes; Pandiella, Atanasio; San Miguel, Jesús F.;
展开▼
作者单位

展开▼
年度 2012
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. The synergy of panobinostat plus doxorubicin in acute myeloid leukemia suggests a role for HDAC inhibitors in the control of DNA repair [J] . P Maiso, E Colado, E M Ocio, Leukemia . 2009,第12期

机译：Panobinostat和阿霉素在急性髓细胞白血病中的协同作用提示HDAC抑制剂在控制DNA修复中的作用
2. Reducing TNF receptor 2+ regulatory T cells via the combined action of azacitidine and the HDAC inhibitor, panobinostat for clinical benefit in Acute myeloid leukemia patients [J] . GovindarajC., TanP., WalkerP., Clinical cancer research: an official journal of the American Association for Cancer Research . 2014,第3期

机译：通过阿扎胞苷和HDAC抑制剂panobinostat的联合作用减少TNF受体2+调节性T细胞，对急性髓样白血病患者具有临床益处
3. SUCCESSFUL TREATMENT WITH BORTEZOMIB, PANOBINOSTAT, AND DEXAMETHASONE OF ACUTE MYELOID LEUKEMIA (AML) IN 2ND RELAPSE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION (SCT): THERAPY SELECTED BASED UPON RESULTS OF A PERSONALIZED FLOW CYTOMETRIC SCREEN FOR DRUG SENSITIVITY [J] . Schiff Deborah, Anderson Eric, Roberts William, Pediatric blood & cancer . 2018,第Suppla1期

机译：在同种异体干细胞移植（SCT）中，用二进制复发（SCT）的急性髓性白血病（AML）的肉氨基蛋白酶和地塞米松的成功治疗：基于个性化流动细胞筛网的药物敏感性的结果选择治疗
4. Azanudeoside DNA Methyltransferase Inhibitor Drugs: Update on Clinical Applications in Myelodysplastic Syndromes and Acute Myeloid Leukemia [C] . Michael Lubbert, Michael Daskalakis, Philipp N. Ser, Weissenburg Symposium Biriciana . 2016

机译：硫代稳产苷DNA甲基转移酶抑制剂药物：更新骨髓增生综合征和急性髓性白血病的临床应用
5. Loss of Egr1 plays a role in murine leukemogenesis and may play a role in the development of acute myeloid leukemia and therapy-related acute myeloid leukemia. [D] . Joslin, John M. 2006

机译：Egr1的丢失在小鼠白血病的发生中起作用，并且可能在急性髓细胞性白血病和与治疗有关的急性髓细胞性白血病的发展中起作用。
6. Myeloid Neoplasia: Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells [O] . Warren Fiskus, Yongchao Wang, Arun Sreekumar, -1

机译：骨髓瘤形成：与组蛋白甲基转移酶EZH2抑制剂3-deazaneplanocin A和组蛋白脱乙酰基酶抑制剂panobinostat联合后生治疗人AML细胞
7. Reducing TNF Receptor 2+ Regulatory T Cells via the Combined Action of Azacitidine and the HDAC Inhibitor, Panobinostat for Clinical Benefit in Acute Myeloid Leukemia Patients [O] . Chindu Govindaraj, Peter Tan, Patricia Walker, 2013

机译：通过偶氮辛胺和HDAC抑制剂，Panobinostat在急性髓性白血病患者中临床益处的组合作用减少TNF受体2+调节T细胞

The synergy of panobinostat plus doxorubicin in acute myeloid leukemia suggests a role for HDAC inhibitors in the control of DNA repairSynergy of panobinostat and doxorubicin in AML

著录项

相似文献

相关主题

期刊订阅